The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
NCT06489184 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 490
Last updated 2024-07-05
Summary
This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
Conditions
Interventions
- DRUG
-
patients with treatment naive or R/R CLL who treatment with Zanubrutinib
Sponsors & Collaborators
-
Peking University People's Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-08-01
- Primary Completion
- 2025-06-01
- Completion
- 2025-12-30
- FDA Drug
- Yes
Countries
- China
Study Locations
More Related Trials
-
Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation
NCT04980859 ·Status: UNKNOWN ·Phase: PHASE3
-
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06544785 ·Status: RECRUITING ·Phase: PHASE2
-
Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice
NCT04094051 ·Status: UNKNOWN
-
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT06637501 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
NCT06697184 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT03734016 ·Status: COMPLETED ·Phase: PHASE3
-
Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL
NCT06849713 ·Status: RECRUITING ·Phase: PHASE2
-
Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL
NCT05287984 ·Status: UNKNOWN ·Phase: PHASE2
-
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
NCT06341556 ·Status: RECRUITING ·Phase: PHASE2
-
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT06547944 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
NCT05944978 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
NCT05950997 ·Status: RECRUITING ·Phase: NA
-
A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies
NCT05269940 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
NCT05326308 ·Status: RECRUITING
-
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
NCT02315768 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
NCT03932331 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia
NCT02042911 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL
NCT05365100 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Study of BN104 in the Treatment of Acute Leukemia
NCT06052813 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
NCT05579132 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib
NCT05491044 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT04684147 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2